<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02661555</url>
  </required_header>
  <id_info>
    <org_study_id>Brain health in MS</org_study_id>
    <nct_id>NCT02661555</nct_id>
  </id_info>
  <brief_title>Aerobic Exercise and Brain Health in Multiple Sclerosis</brief_title>
  <official_title>Effects of Aerobic Exercise on Brain Health in People With Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jascha fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Knud and Edith Eriksens memorial fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Augustinus fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Masku Neurological Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the project is to investigate how aerobic exercise affects brain volume,&#xD;
      specific brain regions, neurotrophins and cognition in patients with multiple sclerosis.&#xD;
&#xD;
      The study will be a single blinded randomized controlled trial with a 6 months intervention.&#xD;
&#xD;
      It is hypothesized that aerobic exercise can slow down brain atrophy, increase the size of&#xD;
      hippocampus, upregulate the secretion of neurotrophins and improve cognitive performance in&#xD;
      people with multiple sclerosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple Sclerosis (MS) is a physically and cognitively disabling, chronic autoimmune disease&#xD;
      of unknown etiology. It is the most common neurological disease affecting young adults in&#xD;
      Western countries. According to the Danish MS Registry the prevalence has increased markedly&#xD;
      over the last 40 years for particularly women, and today there are approximately 14.000&#xD;
      patients with MS (PwMS) in Denmark.&#xD;
&#xD;
      The pathological hallmark of MS is sclerotic plaque. Plaques in the central nervous system&#xD;
      (CNS) can be detected in vivo using magnetic resonance imaging (MRI). Both the accumulation&#xD;
      of lesions and the accelerated whole-brain atrophy correlate with the progressing physical&#xD;
      and cognitive disabilities that clinically characterize PwMS.&#xD;
&#xD;
      The disease causes damage of both white and grey matter in the CNS, leading to whole brain&#xD;
      atrophy and topographically specific atrophy within the hippocampus and the frontal and&#xD;
      temporal cortices. The degradation of the CNS manifests as cognitive and physical disability.&#xD;
      Cognitive impairment is estimated to affect up to 65% of PwMS, making it one of the most&#xD;
      common and disabling symptoms of MS. Medical therapies for cognitive impairment in MS have so&#xD;
      far proved ineffective. Collectively, the prevalence, impact and missing treatments highlight&#xD;
      the importance of alternative approaches towards preservation of cognitive function. Despite&#xD;
      equivocal findings, aerobic exercise represents a promising approach towards preservation or&#xD;
      even expansion of hippocampal volume and cognitive functioning in MS. No longitudinal&#xD;
      randomized controlled trial (RCT) study has so far applied the MRI technique when evaluating&#xD;
      the potential neuro-protective effect of exercise on brain structure and function in MS.&#xD;
      Also, given the scarcity of effective treatments for cognitive impairment in MS, a&#xD;
      longitudinal exercise intervention evaluating the potential effect of aerobic exercise on&#xD;
      cognition is urgently needed in MS.&#xD;
&#xD;
      The purpose of the present project is to investigate how aerobic exercise affects brain&#xD;
      volume, specific brain regions, neurotrophins and cognition in PwMS.&#xD;
&#xD;
      It is hypothesized that aerobic exercise can slow down brain atrophy, increase the size of&#xD;
      hippocampus, upregulate the secretion of neurotrophins and improve cognitive performance in&#xD;
      people with MS.&#xD;
&#xD;
      The study will be a single blinded RCT. The exercise intervention will contain 6 months of&#xD;
      aerobic training (bicycling, rowing and cross trainer) performed two times a week at moderate&#xD;
      to high intensity and under supervision. The control group will be &quot;living as usual&quot; and will&#xD;
      be offered the same exercise intervention after a 6 month period. A total of approximately 85&#xD;
      PwMS will be expected to be enrolled. The primary outcome of the study will be brain atrophy&#xD;
      determined by MRI.&#xD;
&#xD;
      The current interdisciplinary project aims to document and understand the possible&#xD;
      neuro-protective effects of exercise in MS. This would be of high relevance to PwMS (and&#xD;
      other neurological pathologies). From a societal perspective it would help optimize MS&#xD;
      rehabilitation and subsequently reduce MS related costs due to disability. In case of&#xD;
      positive findings, this would provide the first convincing human evidence of a disease&#xD;
      modifying effect of exercise in MS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">May 2019</completion_date>
  <primary_completion_date type="Actual">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage brain volume change</measure>
    <time_frame>0, 24 and 48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognition measured by the Brief Repeatable Battery of Neuropsychological Tests</measure>
    <time_frame>0, 24 and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood samples: Cytokines and neurotrophins</measure>
    <time_frame>0, 24 and 48 weeks</time_frame>
    <description>brain derived neurotrophic factor and key cytokines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VO2max</measure>
    <time_frame>0, 24 and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regional volume change changes (e.g. hippocampus, thalamus)</measure>
    <time_frame>0, 24 and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Fatigue Impact Scale</measure>
    <time_frame>0, 24 and 48 weeks</time_frame>
    <description>Lower score is better. Range 0-84</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue Severity Scale</measure>
    <time_frame>0, 24 and 48 weeks</time_frame>
    <description>Lower score is better. Range 9-63.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Depression Inventory</measure>
    <time_frame>0, 24 and 48 weeks</time_frame>
    <description>Lower score is better. Range 0-50</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form 36</measure>
    <time_frame>0, 24 and 48 weeks</time_frame>
    <description>Higher score is better. Each item is scored on a 0 to 100 range.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Sclerosis Impact Scale 29</measure>
    <time_frame>0, 24 and 48 weeks</time_frame>
    <description>Converted to a 0-100 scale where 100 indicates greater impact of disease on daily function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-min walk test</measure>
    <time_frame>0, 24 and 48 weeks</time_frame>
    <description>Walk as far as possible in 6 minutes. Higher is better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Six Spot Step Test</measure>
    <time_frame>0, 24 and 48 weeks</time_frame>
    <description>Complete the task as fast as possible. Faster is better.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Brain Atrophy</condition>
  <condition>Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Aerobic exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aerobic exercise two times per week for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Habitual lifestyle</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Habitual lifestyle the first 24 weeks. Will be offered the same exercise intervention after 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Aerobic exercise</intervention_name>
    <arm_group_label>Aerobic exercise</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed consent&#xD;
&#xD;
          -  Definite MS diagnosis&#xD;
&#xD;
          -  Be clarified with the diagnosis and treatment&#xD;
&#xD;
          -  Expectedly able to carry out the aerobic training / test&#xD;
&#xD;
          -  Expanded Disability Status Scale (EDSS) score â‰¤6.0&#xD;
&#xD;
          -  Must be able to transport themselves to and from training sessions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Dementia, alcohol abuse or pacemaker&#xD;
&#xD;
          -  Medical comorbidity such as cardiovascular, respiratory, orthopedic or metabolic&#xD;
             disorders or other concurrent diseases causing disability and hindering participation&#xD;
             in the intervention&#xD;
&#xD;
          -  Disease relapse in a 8 week period prior to study start&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Metallic implants hindering the MRI scans.&#xD;
&#xD;
          -  Expected training attendance below 85%&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin L Christensen, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Aarhus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sport Science, Department of Public Health, Aarhus University</name>
      <address>
        <city>Aarhus</city>
        <state>Aarhus C</state>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>January 15, 2016</study_first_submitted>
  <study_first_submitted_qc>January 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2016</study_first_posted>
  <last_update_submitted>May 28, 2021</last_update_submitted>
  <last_update_submitted_qc>May 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

